Back to Browse Journals » Vascular Health and Risk Management » Volume 6

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

Authors Katarina Raslova

Published Date May 2010 Volume 2010:6 Pages 399—410

DOI http://dx.doi.org/10.2147/VHRM.S10397

Published 24 May 2010

Katarina Raslova

Metabolic Center Ltd and Slovak Medical University, Bratislava, Slovak Republic

Abstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin. Modification of the human insulin molecule results in a slower distribution to peripheral target tissues, a longer duration of action with stable concentrations and thus a lower rate of hypoglycemia. Insulin detemir is a basal insulin analog that provides effective therapeutic options for patients with type 1 and type 2 diabetes. For glycemic control, no significant differences were found in HbA1c levels compared with NPH and insulin glargine. It is comparable with insulin glargine in significantly reducing rates of all types of hypoglycemia. Clinical studies have demonstrated that detemir is responsible for significantly lower within-subject variability and no or less weight gain than NPH insulin and glargine. Recent pharmacodynamic studies have shown that detemir can be used once daily in many patients with diabetes. Together with patient-friendly injection devices and dose adjustments, it provides a treatment option with the potential to lower the key barriers of adherence to insulin therapy in type 2 diabetes. Recent guidelines for treatment of type 2 diabetes suggest starting intensive therapy of hyperglycemia at an early stage of diabetes and recommend therapeutic options that provide the possibility of reaching HbA1c goals individually, with a low risk of hypoglycemia or other adverse effects of treatment. The properties of insulin detemir match these requirements.

Keywords: insulin analog, insulin detemir, diabetes mellitus, hypoglycemia, within-subject variability

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Mahabala C, Kamath P, Bhaskaran U, Pai ND, Pai AU

Vascular Health and Risk Management 2013, 9:125-133

Published Date: 24 March 2013

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Emerging options in growth hormone therapy: an update

Kemp SF, Frindik JP

Drug Design, Development and Therapy 2011, 5:411-419

Published Date: 30 August 2011

Low energy nanoemulsification to design veterinary controlled drug delivery devices

Thierry F Vandamme, Nicolas Anton

International Journal of Nanomedicine 2010, 5:867-873

Published Date: 15 October 2010

Biologic response of animals to husbandry stress with implications for biomedical models

Bernadette Earley, Kelly Buckham-Sporer, Sandeep Gupta, et al

Open Access Animal Physiology 2010, 2:25-42

Published Date: 4 August 2010

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009

Alitretinoin – its use in intractable hand eczema and other potential indications

Bibi Petersen, Gregor BE Jemec

Drug Design, Development and Therapy 2009, 3:51-57

Published Date: 5 February 2009

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008